Quantum Genomics announces that the presentation of the results of the
Firibastat, in its phase III FRESH study,
will finally take place on November 7, 2022
as part of a session dedicated to resistant hypertension
at the AHA conference.
Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC)
a biopharmaceutical company specializing in the development of a new class of drugs that act directly on the brain to treat resistant hypertension and heart failure, announces that the presentation of the results of its phase III FRESH study in hypertension resistant, will eventually take place
November 7, 2022, at 3 p.m.
local time, as part of a specific “Late-breaking trials” session that the American Heart Association (AHA) has decided to dedicate to resistant hypertension during its annual congress to be held in Chicago.
The AHA’s annual congress puts resistant hypertension in the spotlight by dedicating a specific “Late-breaking trials” session to it entitled “Resistant hypertension: a pressure cooker *”
Bruno Besse, Medical Director of Quantum Genomics, says:
“By dedicating a specific session
“Late-breaking trials”
to resistant hypertension, the AHA has decided to focus on the global public health issue represented by resistant hypertension, for the management of which there is currently little or no treatment. effective therapeutic alternative. This demonstrates once again the interest of the scientific community for a new therapeutic class, such as that represented by firibastat, making it possible to manage resistant arterial hypertension.”
The results of the FRESH study, presented at the AHA congress by Professor Bakris, will constitute a first key step towards filing the registration dossier with the American and European authorities.
The FRESH study is indeed the first pivotal phase III study aimed at evaluating the efficacy and tolerance of firibastat in the treatment of difficult resistant hypertension. 515 eligible patients with difficult-to-treat or resistant hypertension were randomized to 69 hospitals in Europe, Canada, the United States and Latin America.
Recruitment of the REFRESH study, the second pivotal phase III study of long-term efficacy and safety, with the once-daily formulation of firibastat, is progressing normally.
*Resistant hypertension: a pressure cooker
About Quantum Genomics
Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular drugs, based on the mechanism of inhibition of brain Aminopeptidase A (Brain Aminopeptidase A Inhibition or BAPAI). The only company in the world to pursue this innovative approach directly targeting the brain, it relies on more than twenty years of research from the University of Paris-Descartes and the INSERM/CNRS laboratory directed by Dr. Catherine Llorens-Cortès at France secondary school. Quantum Genomics thus aims to develop innovative treatments for complicated or even resistant arterial hypertension (around 30% of patients are poorly controlled or fail treatment), and heart failure (one out of two patients diagnosed dies within five years).
Based in Paris and New York, the company is listed on the Euronext Growth market in Paris (FR0011648971 – ALQGC) and registered on the American market OTCQX (symbol: QNNTF).
More information on www.quantum-genomics.com, our Twitter and Linkedin accounts
contacts
|
Quantum Genomics | |
|
Communication building (EUROPE) | |
Financial communication and media | |
|
LifeSci (USA) | |
Mike Tattory |
This post has the “? Actusnews SECURITY MASTER” service.
– SECURITY MASTER Key:
xplpksppZWvGmZ1tl55qbmZqm2eSxGicZ5Sal5dta5/KZ2qSlZuXbpSaZnBnmGto
– To check this key:
https://www.security-master-key.com.
Regulated information:
Inside information:
– Other press releases
Full and original press release in PDF format:
https://www.actusnews.com/news/76362-cp-changement-jour-aha-2.pdf
© Copyright Actusnews Wire
Receive the company’s next press releases free of charge by email by subscribing to www.actusnews.com